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Although autoimmune diseases (AIDs) are known to predispose to non‐Hodgkin lymphoma
(NHL), their association with NHL prognosis has rarely been investigated. We examined
associations between autoimmunity and B‐cell NHL onset by comparing AID history
(determined by self‐report and medication review and supplemented by chart review where
possible) among 435 adult B‐NHL patients in Hadassah‐Hebrew University Medical Center,
diagnosed 2009‐2014, and 414 age‐and‐sex frequency‐matched controls. We examined AIDs
as a whole, B‐ and T‐cell–mediated AIDs, and autoimmune thyroid diseases. Among cases,
we used Kaplan‐Meier and Cox regression models to assess the association of AID with over-
all survival and relapse‐free survival, adjusting for prognostically important patient and disease
characteristics such as Ki67% staining, International Prognostic Index, rituximab treatment, and
histological subgroup.
Autoimmune diseases were associated with B‐NHL (odds ratio [OR] = 1.95; 95% confidence
interval (CI), 1.31‐2.92), especially AIDs mediated by B‐cell activation (OR = 5.20; CI, 1.90‐14.3),
which were particularly associated with marginal zone lymphoma (OR = 19.3; CI, 4.59‐80.9). We
found that time to relapse for all B‐NHL patients with AIDs was significantly shorter (mean
of 49.21 mo [±3.22]) than among patients without AID (mean of 59.74 mo [±1.62]), adjusted
hazard ratio [HRadj] = 1.69 (CI, 1.03‐2.79). Specifically, in patients with diffuse large B‐cell
lymphoma, of whom 91.8% had received rituximab, a history of B‐cell–mediated AIDs was
associated with shorter relapse‐free survival and overall survival, HRadj = 8.34 (CI, 3.01‐
23.1) and HRadj = 3.83 (CI, 1.20‐12.3), respectively.
Beyond confirming the well‐known association between AIDs and B‐NHL, we found that AID is
an adverse prognostic factor in B‐cell lymphoma, associated with a shortened time to relapse,
suggesting that there are specific therapeutic challenges in the subgroup of patients suffering
from both these diseases. Further work is required to address mechanisms of resistance to
standard treatment in the setting of AID‐associated B‐NHL. In the era of immunotherapy, these
findings have particular relevance.
KEYWORDS
autoimmune disease, diffuse large B‐cell lymphoma, non‐Hodgkin lymphoma, risk, survival1 | INTRODUCTION
The association between autoimmune diseases (AIDs) and the risk of
developing non‐Hodgkin lymphoma (NHL) has been reported in manyontributions.
wileyonlinelibrary.com/journaclinical and epidemiological studies, including both cohort and case‐
control studies. In an early study conducted in Finland between 1967
and 1973, which included 46 101 patients with rheumatoid arthritis
(RA) followed for 213 911 person‐years, the authors found a 2.8‐fold
increased risk for NHL.1 Another study in Finland followed 676 RA
or Sjögren syndrome (SS) patients between 1970 and 1991 and foundCopyright © 2018 John Wiley & Sons, Ltd.l/hon 1
2 KLEINSTERN ET AL.among the primary SS cases an 8.7‐fold increased risk for NHL.2 In
addition, a cohort study from Canada followed 724 systemic lupus
erythematosus (SLE) cases and found a 5.4‐fold increased risk for
NHL.3 In a meta‐analysis including 20 cohort studies published
between 1974 and 2005, the relative risk of NHL for a variety of AIDs
ranged between 2.5 and 374; specifically, a high risk of NHL
development was found for SS (18.8‐fold increased risk), moderate risk
for SLE (7.4‐fold increased risk), and lower risk for RA (3.9‐fold
increased risk). These findings are further supported by population‐
based studies in the United States, which included 44 350 cases with
lymphoid neoplasms and 122 531 population‐based controls, and
found strong associations for diffuse large B‐cell lymphoma (DLBCL)
with RA (1.4‐fold increased risk) and SS (2.0‐fold increased risk); T‐cell
lymphoma with haemolytic anaemia (9.7‐fold increased risk), psoriasis
(3.1‐fold increased risk), SLE (4.4‐fold increased risk), and coeliac
disease (5.0‐fold increased risk); and marginal zone lymphoma (MZL)
with SS (6.6‐fold increased risk), SLE (2.8‐fold increased risk), and
haemolytic anaemia (7.4‐fold increased risk).5 In addition, in a cohort
study from the Swedish Cancer Registry in Sweden, which followed
878 161 patients for a mean of 9.4 years, with 33 different AIDs,
3096 of them were diagnosed with NHL during follow‐up resulting in
overall standardized incidence ratios for NHL of 1.6 after any AIDs;
27.2 for autoimmune haemolytic anaemia; 7.5 for immune thrombocy-
topenic purpura; 4.1 to 4.9 for polymyositis/dermatomyositis, SS,
coeliac disease, and SLE; 2.0 to 2.6 for RA, systemic sclerosis, Crohn
disease, myasthenia gravis, and sarcoidosis; and 1.4 to 1.5 for
polymyalgia rheumatica, Hashimoto/hypothyroidism and psoriasis
and ulcerative colitis.6
It is now recognized that NHL is a biologically and clinically hetero-
geneous malignancy.7 The International Lymphoma Epidemiology
Consortium (InterLymph), including 17 471 cases and 23 096 controls
from 20 studies,7 reported that AIDs mediated by B‐cell activation
were associated with specific B‐cell lymphoma subtypes and AIDsTABLE 1 Demographic characteristics for controls and cases with overall
Characteristics
DLBCL FL M
N (%) N (%) N
Total no. 182 (41.8) 116 (26.7) 6
Sex Male 84 (46.2) 52 (44.8) 3
Female 98 (53.8) 64 (55.2) 3
Age
Years
<35 19 (10.4) 4 (3.4) 1
35‐54 48 (26.4) 36 (31.0) 2
55‐64 40 (22.0) 37 (31.9) 1
65‐74 44 (24.2) 23 (19.8) 1
≥75 31 (17.0) 16 (13.8) 1
Marital
Status
Single 14 (7.7) 5 (4.3) 3
Married 127 (69.8) 86 (74.1) 4
Other 41 (22.5) 25 (21.6) 1
Ethnicity Ashkenazi 110 (60.5) 73 (62.9) 4
Sephardic 14 (7.7) 6 (5.2) 3
North African 27 (14.8) 24 (20.7) 1
West Asian 31 (17.0) 13 (11.2) 8
Education
Years
0‐8 20 (11.0) 5 (4.3) 3
9‐12 50 (27.5) 29 (25.0) 1
>12 112 (61.5) 82 (70.7) 4
Abbreviations: B‐NHL, B‐cell non‐Hodgkin lymphoma; DLBCL, diffuse large B‐c
*P value calculated for overall B‐NHL versus controls.mediated by T‐cell activation were mainly related to T‐cell lymphoma
to varying degrees.7-9
The association between AID and prognosis in B‐cell NHL (B‐NHL)
has rarely been documented. In contrast, poorer survival for Hodgkin
lymphoma patients with a discharge diagnosis of AID was clearly
shown by Landgren et al10; among 7414 Hodgkin lymphoma patients
and 29 240 controls, they found that female and male patients with
Hodgkin lymphoma had a 1.8‐fold and 1.7‐fold increased relative risk
of dying at 5 years of follow‐up, respectively.10 Only a few studies,
most involving small samples and conducted prior to the near‐universal
use of rituximab, have suggested poorer outcomes among NHL cases
with AIDs.11,12 A study conducted in Sweden among 1523 cases, with
mean follow‐up of 8.8 years, reported that the overall survival (OS)
was marginally poorer among AIDs versus non‐AID–associated NHL,
hazard ratio (HR) = 1.4 (95% confidence intervals [CIs], 1.0‐1.8).13 In
contrast, a study in which only patients with extranodal marginal zone
B‐cell lymphoma of mucosa‐associated lymphoid tissue were included,
found comparable estimated median time to relapse in those both with
and without AIDs.14 The association of AID with lymphoma prognosis
has become increasingly relevant in the era of immunotherapies, since
autoimmunity is a major toxicity of these promising treatments and
clinical trials generally exclude patients with AIDs.
Herein, we aim to examine the association between AIDs and
B‐NHL and the influence of AIDs on OS and relapse‐free survival
(RFS) after the introduction of rituximab as standard of care.2 | METHODS
We performed a hospital‐based case‐control study among B‐NHL
adult (>18 y) patients diagnosed between 2009 and 2014 and healthy
age‐and‐sex frequency‐matched controls who accompanied patients
to the hospital.15 Participants answered interviewer‐administeredB‐NHL and subtypes
ZL Overall B‐NHL Controls
P*
(%) N (%) N (%)
5 (14.9) 435 (100) 414 (100)
4 (52.3) 211 (48.5) 184 (44.4) .23
1 (47.7) 224 (51.5) 230 (55.6)
(1.5) 28 (6.4) 45 (10.9) .001
3 (35.4) 122 (28.0) 111 (26.8)
7 (26.2) 114 (26.2) 111 (26.8)
3 (20.0) 97 (22.3) 111 (26.8)
1 (16.9) 74 (17.0) 36 (8.7)
(4.6) 26 (6.0) 14 (3.4) <.0001
9 (75.4) 311 (71.5) 382 (92.3)
3 (20.0) 98 (22.5) 18 (4.3)
4 (67.7) 271 (62.3) 289 (70.0) .02
(4.6) 28 (6.5) 34 (8.2)
0 (15.4) 68 (15.6) 46 (11.1)
(12.3) 68 (15.6) 44 (10.97)
(4.6) 33 (7.6) 7 (1.7) <.0001
6 (24.6) 117 (27.0) 110 (26.6)
6 (70.8) 284 (65.4) 297 (71.7)
ell lymphoma; FL, follicular lymphoma; MZL, marginal zone lymphoma.
KLEINSTERN ET AL. 3questionnaires (see detailed methods15) including a history of AIDs and
medications. Autoimmune disease status was confirmed using
medication history (for both cases and controls) and review of
medical records where possible including the presence of specific
autoantibodies. Sociodemographic variables in cases and controls were
compared using 2‐sided Fisher exact and χ2 tests. We examined the
associations of AIDs as a whole, B‐ and T‐cell–mediated AIDs (as per
InterLymph criteria16), and autoimmune thyroid diseases with overall
B‐NHL, and specifically DLBCL, follicular lymphoma (FL), and MZL
subtypes. B‐cell–mediated AIDs included RA, SS, SLE, autoimmune
haemolytic anaemia, antiphospholipid syndrome, polymyalgia
rheumatica, cryoglobulinaemia vasculitis, and undefined B‐cell AIDs;
T‐cell AIDs included coeliac disease, ulcerative colitis, Crohn disease,
psoriasis, polymyositis, chronic inflammatory demyelinating polyneu-
ropathy, sarcoidosis, multiple sclerosis, scleroderma, and immune
thrombocytopenic purpura; autoimmune thyroid diseases included
Hashimoto thyroiditis and Grave disease. We used logistic regression
to assess the association of AID with lymphoma odds, adjusting
for education (y), marital status, and ethnicity on the basis of
grandparents' origin.TABLE 2 History of autoimmune diseases for controls and cases with ove
Characteristics
DLBCL FL
N (%) N
Total no. 182 (41.8) 11
AIDs (any) 41 (22.5) 24
AIDs B‐cell mediated 8 (4.4) 5
Rheumatoid arthritis 3 (37.5) 3
Sjogren's syndrome 1 (12.5) 1
Systemic lupus erythematosus 3 (37.5) …
Autoimmune haemolytic anaemia … … …
Antiphospholipid syndrome 1 (12.5) …
Polymyalgia rheumatica … … 1
Cryoglobulinaemic vasculitis … … …
Undefined B‐cell … … …
AIDs T‐cell mediated 14 (7.7) 7
Coeliac disease … … …
Ulcerative colitis 3 (21.4) …
Crohn disease 1 (7.1) 1
Psoriasis 9 (64.3) 5
Polymyositis … … …
Chronic inflammatory demyelinating polyneuropathy … … 1
Sarcoidosis 1 (7.1) …
Multiple sclerosis … … …
Scleroderma … … …
Immune thrombocytopenic purpura … … …
AID—thyroid 22 (12.1) 13
Hypothyroidism (other) 21 (95.5) 12
Graves hyperthyroidism 1 (4.5) 1
Rituximab treatmenta 167 (91.8) 77
Abbreviations: AIDs, autoimmune diseases; B‐NHL, B‐cell non‐Hodgkin lympho
marginal zone lymphoma.
Values were missing for ≤1% of exposure variables.
aSome cases with indolent lymphoma were untreated at the time of follow‐up,
*P value calculated for overall B‐NHL versus controls.Among cases only, we measured OS (date of diagnosis to date of
death or last follow‐up) and RFS (remission date to date of first relapse
or last follow‐up) comparing those with/without AID using Kaplan‐
Meier curves for the AID and non‐AID group and the log rank test
for statistical comparison. We then constructed multivariable Cox
regression models adjusting for Ki67% staining, International Prognos-
tic Index17 score, rituximab treatment, and histological subgroup.
Agreement of self‐reported AIDs and medication history with
medical records including the presence of specific autoantibodies
was assessed using the Kappa score with 95% CIs.3 | RESULTS AND DISCUSSION
Among 435 B‐NHL cases and 414 healthy controls, the median age at
diagnosis/interview was 60 years, with 48.5% and 44.4% males,
respectively. The most common B‐NHL subtype was DLBCL (41.8%)
followed by FL (26.7%) and MZL (14.9%). During the study period,
90% of eligible B‐NHL cases were recruited.15 Demographic
characteristics are shown inTable 1. Rituximab treatment was commonrall B‐NHL and subtypes and rituximab treatment for cases
MZL Overall B‐NHL Controls
P*
(%) N (%) N (%) N (%)
6 (26.7) 65 (14.9) 435 (100) 414 (100)
(20.7) 15 (23.1) 97 (22.5) 57 (13.8) .001
(4.3) 7 (10.8) 26 (5.9) 5 (1.2) <.0001
(60.0) 2 (28.6) 10 (38.5) 3 (60.0)
(20.0) 1 (14.3) 3 (11.5) … …
… 2 (28.6) 5 (19.2) 2 (40.0)
… 2 (28.6) 4 (15.4) … …
… … … 1 (3.8) … …
(20.0) … … 1 (3.8) … …
… … … 1 (3.8) … …
… … … 1 (3.8) … …
(6.0) 5 (7.7) 31 (7.1) 19 (4.6) .14
… 1 (20.0) 1 (3.2) 1 (5.3)
… 2 (40.0) 6 (19.4) …
(14.3) … … 2 (6.5) 2 (10.5)
(71.4) 1 (20.0) 17 (54.8) 12 (63.2)
… 1 (20.0) 1 (3.2) … …
(14.3) … … 1 (3.2) … …
… … … 2 (6.5) 1 (5.3)
… … … … … 2 (10.5)
… … … … … 1 (5.3)
… … … 1 (3.2) … …
(11.2) 6 (9.2) 51 (11.8) 34 (8.2) .08
(92.3) 6 (100) 49 (96.0) 32 (94.1)
(7.7) … … 2 (4.0) 2 (5.9)
(66.4) 27 (41.5) 308 (70.8) … …
ma; DLBCL, diffuse large B‐cell lymphoma; FL, follicular lymphoma; MZL,
observed by watchful waiting.
4 KLEINSTERN ET AL.among B‐NHL cases with 70.8%; it was most common among DLBCL
cases with 91.8% followed by FL with 66.4% and MZL with 41.5%.
Concordance between self‐reported AID and medical records was
moderate (Kappa = 0.60; 95% CI, 0.53‐0.66).
Autoimmune diseases were present in 97 (22.5%) B‐NHL cases
and 57 (13.8%) controls; specifically, AIDs were most common in
MZL (23.1%), followed by DLBCL (22.5%) and FL (20.7%) (Table 2).
Autoimmune diseases were positively associated with B‐NHL (odds
ratio [OR] = 1.95; 95% CI, 1.31‐2.92), DLBCL (OR = 1.96; 95% CI,
1.16‐3.31), FL (OR = 2.13; 95% CI, 1.18‐3.84), and MZL (OR = 2.38,
95% CI, 1.15‐4.93). Autoimmune diseases mediated by B‐cell activa-
tion were present in 26 (5.9%) B‐NHL cases and 5 (1.2%) controls;
specifically, AIDs mediated by B‐cell activation were most common
in MZL with 10.8%, followed by DLBCL with 4.4% and FL with 4.3%
(Table 2). Autoimmune diseases mediated by B‐cell activation were
strongly associated with B‐NHL overall (OR = 5.20; 95% CI, 1.90‐
14.26), notably with MZL (OR = 19.3; 95% CI, 4.59‐80.9) and less with
FL (OR = 4.27; 95% CI, 1.08‐16.9) subtypes. Autoimmune diseases
mediated by T‐cell activation were present in 31 (7.1%) B‐NHL cases
and 19 (4.6%) controls; specifically, AIDs mediated by T‐cell activation
were most common in both DLBCL and MZL with 7.7%, followed by
FL with 6.0% (Table 2); however, no significant association was found
between AIDs mediated by T‐cell activation and B‐NHL or subtypes.
Autoimmune thyroid diseases were present in 51 (11.8%) B‐NHL cases
and 34 (8.2%) controls; specifically, autoimmune thyroid diseases were
most common in DLBCL with 21.1% followed by FL with 11.2% andFIGURE 1 Overall and relapse‐free survival by B‐cell–mediated autoimmun
lymphoma. Kaplan‐Meier survival curves by B‐cell–mediated autoimmune
lymphoma (B‐NHL); (B) overall survival for diffuse large B‐cell lymphoma (D
survival for DLBCL. P values derive from log rank testsMZL with 9.2% (Table 2); here again, no associations between autoim-
mune thyroid diseases and B‐NHL or subtypes were observed.
After a median follow‐up of 42 months (range, 2‐75), we found
that mean time to relapse was significantly shorter (49.21 mo
[±3.22]) for B‐NHL patients with AIDs compared with those without
(59.74 mo [±1.62]) (adjusted HR [HRadj] = 1.69; 95% CI, 1.03‐2.79),
especially for AIDs mediated by B‐cell activation (HRadj = 3.41; 95%
CI, 1.77‐6.55). In DLBCL in particular, both RFS and OS were markedly
shortened in the presence of B‐cell–mediated AIDs (Figure 1),
HRadj = 8.34 (95% CI, 3.01‐23.1) and HRadj = 3.83 (95% CI, 1.20‐
12.3) after adjusting for International Prognostic Index, Ki67 and ritux-
imab, respectively. In addition, among MZL cases, RFS was adversely
affected in those with B‐cell mediated AIDs (HRadj = 13.4; 95% CI,
2.48‐72.6).
Our study included some limitations. One limitation was that
medical records were largely unavailable to confirm AID status among
controls (in whom only self‐report and medication history were
available). Resulting misclassification or information bias could have
affected the OR estimates (but not the survival findings) biasing them
toward the null in the assessment of the association of autoimmunity
with NHL. We may have underestimated the prevalence of AID among
cases; however, the prevalence of AIDs mediated by B‐cell activation
among controls (1.2%) was consistent with reports in the American
population (approximately 1%).18
The distribution of specific AIDs differed from other studies.
Specifically, among MZL cases with AID, 23.1% in our series ande diseases for all B‐cell non‐Hodgkin lymphoma and diffuse large B‐cell
diseases (AIDs): (A) overall survival for overall B‐cell non‐Hodgkin
LBCL); (C) relapse‐free survival for overall B‐NHL; (D) relapse‐free
KLEINSTERN ET AL. 530% in the InterLymph series9 had Sjogren syndrome, while they
represented 71% in Wöhrer study, which concentrated solely on
extranodal. A distinction between MZL subtypes was not made in
our study and is not always possible in case control studies.
Our strict definition of autoimmunity among cases may have
affected the survival analysis, since it may have excluded milder cases
in the AID subgroup. Compared with our study, the follow‐up in the
Wöhrer study of extranodal MZL was longer than our series and during
the first 3 years of follow‐up relapses indeed appeared to be more
common in the autoimmune group. Longer follow‐up of our patients
and further studies examining extranodal vs nodal and splenic MZL
are indeed warranted to further examine the effect of AID on survival
and risk of relapse in all subtypes of B‐NHL. Our findings should not
call for overtreatment in extranodal MZL cases, but do call for
increased vigilance, especially in DLBCL accompanied by AID.
In conclusion, beyond confirming the well‐known association
between B‐NHL and AIDs, we found that AID is an adverse prognostic
factor in B‐NHL, associated with poorer OS and RFS in DLBCL. These
findings are somewhat surprising given the beneficial effects of rituxi-
mab in many B‐cell mediated AIDs19 and its nearly ubiquitous use in
current therapy of DLBCL. They are also of concern given the limita-
tion (and frequent contraindication) of immunotherapy administration
in patients with active AIDs.
The inferior RFS and OS in DLBCL suggest the presence of
mechanisms of resistance to traditional chemoimmunotherapy in
AID‐associated lymphoma. While mechanisms for lymphoma transfor-
mation in AID have been suggested,18 none have yet been raised
regarding prognosis or response to therapy. Further work should
examine cell‐of‐origin and molecular prognostic markers in AID‐
associated NHL, and attention to this risk group should lead to more
effective therapies in these unusual lymphomas.ETHICS STATEMENT
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